The new trial included 1,077 healthy adults aged 18 to 55 years with no history of COVID-19.
Data from the German part of the trial I indicated the vaccine (BNT162b1) elicited strong immune (T cell) and antibody responses to SARS-CoV-2, the current strain of the pandemic.
There were no serious adverse event related to the vaccine; fatigue and headache were the most commonly reported reactions.
Oxford's Gilbert said the early-stage trial could not determine whether one or two doses would be needed to provide immunity.
Authors of the study suggested that the vaccine should now be tested on older adults, who have weaker immune systems and are considered especially vulnerable to the CCP (Chinese Communist Party) virus.
Suspect arrested in grisly murder of tech CEO
Saleh then fell to the floor, and Haspil allegedly fatally stabbed him multiple times in the torso and neck, Ford said . On Monday, the killer, wearing a three-piece suit and a mask, entered the building's elevator with Saleh.
Meanwhile, the government is hoping to get half a million people to sign up to trials of vaccines in the United Kingdom through the NHS Covid-19 vaccine research registry website.
His counterpart in the cabinet, Education Secretary Gavin Williamson, said a vaccine for Sky News is "the easiest and fastest way out of this crisis".
The British government has already ordered 100 million doses of the potential vaccine, which is among dozens of vaccine candidates worldwide.
The second trial, led by China's Jiangsu Provincial Center for Disease Control and Prevention, used a weakened human cold virus modified to deliver genetic material that teaches cells to recognise the novel coronavirus.
"We believe both may play an important role in achieving effective clearance of a pathogen such as SARS-CoV-2".
A coronavirus vaccine that has been developed by the University of Oxford appears to be "safe" and trains the immune system to fight the virus, according to recent trials. It's hard for us to compare our vaccine results to other people's vaccines.